MARKET

CDNA

CDNA

CareDx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

90.50
-0.75
-0.82%
Closed 16:57 06/14 EDT
OPEN
90.97
PREV CLOSE
91.25
HIGH
92.77
LOW
90.26
VOLUME
623.17K
TURNOVER
--
52 WEEK HIGH
99.83
52 WEEK LOW
29.86
MARKET CAP
4.71B
P/E (TTM)
-313.3657
1D
5D
1M
3M
1Y
5Y
Insider Trends: Selling By Insiders Lingers at CareDx
MT Newswires · 4d ago
CareDx Acquires Transplant Hero, Shares Rise
The shares of CareDx (CDNA) rose 1.4% to $88.59 on June 8 after it acquired Transplant Hero, a New York-based app provider that focuses on helping transplant patients manage their medications. The financial terms of the deal have not been disclosed so far....
SmarterAnalyst · 5d ago
CareDx congratulates Hannah Valantine for her State of the Art Lecture at ATC on Transplant Equity
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, congratulates Hannah Valant...
GlobeNewswire · 5d ago
CareDx buys Transplant Hero medication management application
CareDx (CDNA) has acquired Transplant Hero LLC, a New York-based provider of a mobile application promoting the needs of transplant patients.The commercial terms were not disclosed.The acquisition of Transplant Hero
Seekingalpha · 6d ago
CareDx To Acquire Transplant Hero; Terms Not Disclosed
 CareDx, Inc. (NASDAQ:CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients
Benzinga · 6d ago
CareDx Buys Medication Management App Transplant Hero
MT Newswires · 06/08 08:06
Goldman Sachs picks the health tech stocks set for a post-pandemic boom
Testing for the coronavirus is here to stay and the high-margin health diagnostics industry is set for a boost, Goldman said.
CNBC.com · 06/08 05:08
CareDx Presents Landmark KOAR-1000 Data, Demonstrating Higher 1-Year Graft Survival and Reduction in Biopsies through ARTS Surveillance
KOAR is the largest prospective validation study on AlloSure surveillance with over 1,500 patients enrolledSOUTH SAN FRANCISCO, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the disco...
GlobeNewswire · 06/07 11:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CDNA. Analyze the recent business situations of CareDx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CDNA stock price target is 97.33 with a high estimate of 105.00 and a low estimate of 90.00.
EPS
Institutional Holdings
Institutions: 332
Institutional Holdings: 61.79M
% Owned: 118.70%
Shares Outstanding: 52.05M
TypeInstitutionsShares
Increased
72
4.58M
New
47
2.61M
Decreased
94
5.13M
Sold Out
31
652.15K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.10%
Pharmaceuticals & Medical Research
+0.13%
Key Executives
Chairman/Executive Director
Peter Maag
President/Chief Executive Officer/Director
Reginald Seeto
Chief Financial Officer
Ankur Dhingra
Chief Marketing Officer
Sasha King
Vice President/Controller
Marcel Konrad
Lead Director/Independent Director
Michael Goldberg
Independent Director
George Bickerstaff
Independent Director
Frederick Cohen
Independent Director
Grace Colon
Independent Director
Fred Cohen
Independent Director
Christine Cournoyer
Independent Director
William Hagstrom
Independent Director
Ralph Snyderman
No Data
  • All
  • Financials
  • Insiders
More
About CDNA
CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company's commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.

Webull offers kinds of CareDx Inc stock information, including NASDAQ:CDNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CDNA stock methods without spending real money on the virtual paper trading platform.